A Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ≥18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 syst...

Title

Code

CL3-95031-007

Type

Sperimentale con farmaco

Start Year

2025

Status

In Corso

Principal Investigator

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio prot. CL3-95031-007

Monday 20 January 2025, 17:04

PG0000329_2025_Stampa_unica.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

IRCCS

ISTITUTO ORTOPEDICO RIZZOLI

A Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ≥18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 syst...

Principal Investigator

Documents and Videos attachament

You might also be interested in

Sito Web Istituto Ortopedico Rizzoli

A Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ≥18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 syst...

Principal Investigator

Documents and Videos attachament

You might also be interested in